IMNN
Price
$1.25
Change
+$0.06 (+5.04%)
Updated
Oct 22 closing price
Capitalization
7.01M
20 days until earnings call
Intraday BUY SELL Signals
REPL
Price
$11.99
Change
+$0.27 (+2.30%)
Updated
Oct 22 closing price
Capitalization
1.13B
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMNN vs REPL

IMNN vs REPL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
IMNN vs. REPL commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNN is a StrongBuy and REPL is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for IMNN with price predictions
Oct 22, 2026

IMNN's RSI Indicator ascending out of oversold territory

The RSI Oscillator for IMNN moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 57 similar instances when the indicator left oversold territory. In 45 of the 57 cases the stock moved higher. This puts the odds of a move higher at 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 76 cases where IMNN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on IMNN as a result. In 70 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for IMNN just turned positive on October 21, 2026. Looking at past instances where IMNN's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.

Following a +23.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNN advanced for three days, in 128 of 178 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

IMNN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for IMNN entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.675) is normal, around the industry mean (2.973). P/E Ratio (-0.428) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. IMNN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for REPL with price predictions
Oct 22, 2026

REPL's RSI Indicator ascends from oversold territory

The RSI Indicator for REPL moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 42 similar instances when the indicator left oversold territory. In 37 of the 42 cases the stock moved higher. This puts the odds of a move higher at 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 59 cases where REPL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.

Following a +4.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 184 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

REPL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on REPL as a result. In 69 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for REPL turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 42 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

REPL moved below its 50-day moving average on October 02, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for REPL crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.693) is normal, around the industry mean (2.973). P/E Ratio (-3.806) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
IMNN vs REPL: Fundamental Ratings
IMNN
REPL
OUTLOOK RATING
1..100
333
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
8734
P/E GROWTH RATING
1..100
1658
SEASONALITY SCORE
1..100
9090

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMNN's Valuation (69) in the Medical Specialties industry is in the same range as REPL (77) in the Biotechnology industry. This means that IMNN’s stock grew similarly to REPL’s over the last 12 months.

IMNN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as REPL (100) in the Biotechnology industry. This means that IMNN’s stock grew similarly to REPL’s over the last 12 months.

REPL's SMR Rating (99) in the Biotechnology industry is in the same range as IMNN (100) in the Medical Specialties industry. This means that REPL’s stock grew similarly to IMNN’s over the last 12 months.

REPL's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for IMNN (87) in the Medical Specialties industry. This means that REPL’s stock grew somewhat faster than IMNN’s over the last 12 months.

IMNN's P/E Growth Rating (16) in the Medical Specialties industry is somewhat better than the same rating for REPL (58) in the Biotechnology industry. This means that IMNN’s stock grew somewhat faster than REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMNNREPL
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
75%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
79%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (IMNN: $1.25 vs. REPL: $11.99)
Brand notoriety: IMNN and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMNN: 31% vs. REPL: 81%
Market capitalization -- IMNN: $7.01M vs. REPL: $1.13B
IMNN [@Biotechnology] is valued at $7.01M. REPL’s [@Biotechnology] market capitalization is $1.13B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMNN’s FA Score shows that 1 FA rating(s) are green while REPL’s FA Score has 0 green FA rating(s).

  • IMNN’s FA Score: 1 green, 4 red.
  • REPL’s FA Score: 0 green, 5 red.
According to our system of comparison, REPL is a better buy in the long-term than IMNN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMNN’s TA Score shows that 6 TA indicator(s) are bullish while REPL’s TA Score has 4 bullish TA indicator(s).

  • IMNN’s TA Score: 6 bullish, 2 bearish.
  • REPL’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, IMNN is a better buy in the short-term than REPL.

Price Growth

IMNN (@Biotechnology) experienced а +17.92% price change this week, while REPL (@Biotechnology) price change was +2.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.

Reported Earning Dates

IMNN is expected to report earnings on Nov 12, 2026.

REPL is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IMNN
Daily Signal:
Gain/Loss:
REPL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

IMNN and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMNN has been loosely correlated with ABVX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNN jumps, then ABVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMNN
1D Price
Change %
IMNN100%
+5.04%
ABVX - IMNN
58%
Loosely correlated
-3.49%
REPL - IMNN
57%
Loosely correlated
+2.30%
DNLI - IMNN
30%
Poorly correlated
-0.11%
BRNS - IMNN
29%
Poorly correlated
N/A
IVVD - IMNN
28%
Poorly correlated
-4.57%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SBSI31.630.84
+2.73%
Southside Bancshares Inc
FFIN30.330.56
+1.88%
First Financial Bankshares
PED14.780.11
+0.75%
PEDEVCO Corp
LYV174.500.16
+0.09%
Live Nation Entertainment
QNME0.44-0.04
-7.91%
Quanome Technologies Inc